Session Details
Oral Presentation 9 : Vaccine development
Sun. Sep 28, 2025 9:30 AM - 10:30 AM JST
Sun. Sep 28, 2025 12:30 AM - 1:30 AM UTC
Sun. Sep 28, 2025 12:30 AM - 1:30 AM UTC
Room 5(2F Meeting Room 204)
Chair:Noriyo Nagata, Ryoma Nakao
[O9-01]ウイルスベクターに対する既得抗体が及ぼすワクチン効果の影響解析
*Toshiki Ito1, Yutaro Yamamoto1, Ryota Watano2, Yuna Sato1, Shinnosuke Aasri1, Sara Nitta1, Hiroaki Mizukami2, Hisatoshi Shida3, Shigeto Yoshida1 (1. Laboratory of Vaccine and Immunology, Department of Pharmaceutical Sciences, Kanazawa Univ., 2. Department of Gene Therapy, Research Center for Molecular Pathophysiology and Therapeutics, Jichi Medical Univ., 3. Center for Research Models of Infectious Diseases, Institute for Medical and Biological Research, Kyoto Univ.)
[O9-02]Clinicaltrials.govに登録されたワクチンFirst in human試験プロトコールデザインの検討
*Yoshiaki Yamagishi1,2, Sumiyuki Nishida3,2, Tomomi Yamada4,2, Yutaka Saisho1,2, Akira Myoi1,2 (1. Medical Center for Translational Research, Department of Medical Innovation, the University of Osaka Hospital, 2. Center for Advanced Modalities and Drug Delivery System, the University of Osaka, 3. Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, the University of Osaka, 4. Data Coordinating Center, Department of Medical Innovation, the University of Osaka Hospital)
[O9-03]Charcterization of outer membrane vesicles produced by a probiotic Escherichia coli Nissle 1917 derivative lacking flagella, colibactin, and endotoxin
*Ryoma Nakao1, Nozomu Obana2, Ryunosuke Tominaga1,3, Kazuyoshi Kawahara4, Ryoko Sato5, Masanori Toyofuku2, Nobuhiko Nomura2, Tomoyo Nakagawa-Nakamura1,3, Tomohiko Nishino3, Kimihiro Abe1, Takehiro Yamaguchi1, Yukihiro Akeda1 (1. JIHS, 2. Univ. Tsukuba, 3. Tokyo Univ. Technology , 4. Kanto Gakuin Univ., 5. MiCAN Technologies, Inc.)
[O9-04]戦略的な研究開発の推進に向けたJIHS国立感染症研究所内のワクチン研究シーズ調査と開発状況の把握
*Chiemi Hotta1,2, Takanori Funaki1, Takayuki Matsumura1,3, Daisuke Akazawa1,4, Masako Nishizawa1,5, Minoru Tobiume1, Hiroyuki Sugiyama1,6, Tomoko Ishihara1, Nozomi Takeshita1, Hiroyuki Noda1,7 (1. Center for Research Planning and Coordination, National Institute of Infectious diseases, Japan Institute for Health security., 2. Division of Virology and Medical Zoology, Chiba Prefectural Institute of Public Health., 3. Research Center for Vaccine Development, National Institute of Infectious diseases, Japan Institute for Health security., 4. Department of Drug Development, National Institute of Infectious diseases, Japan Institute for Health security., 5. AIDS Research Center, National Institute of Infectious diseases, Japan Institute for Health security., 6. Center for Emergency Preparedness and Response, National Institute of Infectious diseases, Japan Institute for Health security., 7. Public Health Bureau, Ministry of Health, Labour and Welfare.)
[O9-05]Research on the Development of a Liver-Stage Malaria Vaccine that Elicits Potent Cellular Immune Responses via Liver-Specific T Cells
*Shinnosuke Asari1, Yutaro Yamamoto1, Megumi Odake1, Haruka Oohara1, sayuri Nakamae2,6, Hiroaki Mizukami3, Hisatoshi Shida4, junyu Jian2, Mayumi Taniguchi2, Makoto Matsumoto5, Shusaku Mizukami2, Katsuyuki Yui2, Shigeru Kawakami5, Shigeto Yoshida1 (1. Laboratory of Vaccine and Immunological Sciences, Division of Pharmaceutical Sciences, Kanazawa University, 2. Institute of Tropical Medicine, Nagasaki University, 3. Gene Therapy Division, Research Center for Molecular Medicine, Jichi Medical University, 4. Primate Models Division, Institute for Life and Medical Sciences, Kyoto University, 5. Division of Immunological Regulation, Graduate School of Biomedical Sciences, Nagasaki University, 6. Department of Clinical Development, Institute of Tropical Medicine, Nagasaki University)
[O9-06]Preclinical trials of a multi-stage Plasmodium vivax malaria vaccine using two viral vectors
*Yutaro Yamamoto Yamamoto1, Naho Shinmura1, Manaka Ono1, Yuma Asaki1, Ammar Hasyim1, Yuna Sato1, Kartika Zainal2, Mitsuhiro Iyori4, Takeshi Morita3, Kouich Watashi3, Hiroaki Mizukami4, Hiromi Sakawaki5, Hisatoshi Shida6, Tomoyuki Miura6, Shigeto Yoshida1 (1. Laboratory of vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Ishikawa, Japan,, 2. Division of Gene Therapy, Jichi Medical University, Shimono, Japan,, 3. Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo, Japan, 4. Department of Pharmaceutical Sciences, Musashino University, Tokyo, Japan, 5. Laboratory of Primate Model, Research Center for Infectious Diseases, Institute for Frontier Life and Medical Science, Kyoto University, Japan, 6. Laboratory of Primate Model, Research Kyoto University Institute for Virus Research, Center for Infectious Disease Model Research, Kyoto University, Japan)